High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations

ABSTRACT To define the extent of sequence conservation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) in vivo, the first 320 amino acids of RT obtained from 2,236 plasma-derived samples from a well-defined cohort of 1,704 HIV-1-infected individuals (457 drug naïve and 1,247 drug treated) were analyzed and examined in structural terms. In naïve patients, 233 out of these 320 residues (73%) were conserved (<1% variability). The majority of invariant amino acids clustered into defined regions comprising between 5 and 29 consecutive residues. Of the nine longest invariant regions identified, some contained residues and domains critical for enzyme stability and function. In patients treated with RT inhibitors, despite profound drug pressure and the appearance of mutations primarily associated with resistance, 202 amino acids (63%) remained highly conserved and appeared mostly distributed in regions of variable length. This finding suggests that participation of consecutive residues in structural domains is strictly required for cooperative functions and sustainability of HIV-1 RT activity. Besides confirming the conservation of amino acids that are already known to be important for catalytic activity, stability of the heterodimer interface, and/or primer/template binding, the other 62 new invariable residues are now identified and mapped onto the three-dimensional structure of the enzyme. This new knowledge could be of help in the structure-based design of novel resistance-evading drugs.

[1]  T. Liljefors,et al.  Identification of a putative binding site for 5-alkyl-benzothiadiazides in the AMPA receptor dimer interface. , 2007, Journal of molecular graphics & modelling.

[2]  E. De Clercq,et al.  The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors , 2005, Molecular Pharmacology.

[3]  Valentina Svicher,et al.  Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.

[4]  S. Sarafianos,et al.  Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. , 2004, Current opinion in structural biology.

[5]  F. Ceccherini‐Silberstein,et al.  Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure , 2004, AIDS.

[6]  Matthew J. Gonzales,et al.  Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.

[7]  T. Steitz,et al.  Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Christopher J. Lee,et al.  Positive Selection Detection in 40,000 HumanImmunodeficiency Virus (HIV) Type 1 Sequences Automatically IdentifiesDrug Resistance and Positive Fitness Mutations in HIV Proteaseand ReverseTranscriptase , 2004, Journal of Virology.

[9]  Joseph P. Bielawski,et al.  Widespread Adaptive Evolution in the Human Immunodeficiency Virus Type 1 Genome , 2003, Journal of Molecular Evolution.

[10]  Victoria A Johnson,et al.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  T. Darden,et al.  Mutations Proximal to the Minor Groove-Binding Track of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Differentially Affect Utilization of RNA versus DNA as Template , 2003, Journal of Virology.

[12]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[13]  Thomas D. Wu,et al.  Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors , 2003, AIDS.

[14]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[15]  Kamalendra Singh,et al.  Insertion of a small peptide of six amino acids into the β7–β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities , 2002, BMC Biochemistry.

[16]  Robert W. Shafer,et al.  Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.

[17]  G. Ippolito,et al.  Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation , 2002, AIDS.

[18]  P Pezzotti,et al.  Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. , 2001, The Journal of infectious diseases.

[19]  R. Shafer,et al.  Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. , 2001, The Journal of infectious diseases.

[20]  Zehava Grossman,et al.  Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B , 2001, AIDS.

[21]  K. Ariyoshi,et al.  Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients , 2001, AIDS.

[22]  R. Esnouf,et al.  Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT. , 2001, Virology.

[23]  T. Talele,et al.  The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. , 2001 .

[24]  F. Gago,et al.  Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. , 2001, Journal of medicinal chemistry.

[25]  K. Hertogs,et al.  Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. , 2001, AIDS.

[26]  Julio S. G. Montaner,et al.  HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort , 2001, AIDS.

[27]  K. Hertogs,et al.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting , 2001 .

[28]  D I Stuart,et al.  Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.

[29]  S. Goff,et al.  Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[31]  Y. Cao,et al.  HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.

[32]  S. Yerly,et al.  Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.

[33]  M A Wainberg,et al.  HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. , 1999, Archives of biochemistry and biophysics.

[34]  R. Esnouf,et al.  Mutational Analysis of Tyr-318 within the Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket of Human Immunodeficiency Virus Type I Reverse Transcriptase* , 1998, The Journal of Biological Chemistry.

[35]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[36]  R. Lee,et al.  The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. , 1998, Biochemistry.

[37]  P. Boyer,et al.  Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase. , 1998, Journal of molecular biology.

[38]  Martin A. Nowak,et al.  The frequency of resistant mutant virus before antiviral therapy , 1998, AIDS.

[39]  G J Pielak,et al.  A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Bambara,et al.  Mutations within the Primer Grip Region of HIV-1 Reverse Transcriptase Result in Loss of RNase H Function* , 1997, The Journal of Biological Chemistry.

[41]  S. L. Le Grice,et al.  Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. , 1996, Biochemistry.

[42]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[43]  Samuel H. Wilson,et al.  Role of the "Helix Clamp" in HIV-1 Reverse Transcriptase Catalytic Cycling as Revealed by Alanine-scanning Mutagenesis (*) , 1996, The Journal of Biological Chemistry.

[44]  A. Hughes,et al.  Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). , 1995, Molecular biology and evolution.

[45]  C. Hutchison,et al.  Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. , 1995, Nucleic acids research.

[46]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[47]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[48]  Samuel H. Wilson,et al.  Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an alpha-helix in the thumb subdomain. , 1994, The Journal of biological chemistry.

[49]  H. Heumann,et al.  The 'helix clamp' in HIV-1 reverse transcriptase: a new nucleic acid binding motif common in nucleic acid polymerases. , 1994, Nucleic acids research.

[50]  P. Boyer,et al.  Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. , 1994, Journal of molecular biology.

[51]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[52]  T. Steitz,et al.  Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Boyer,et al.  Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Kunkel,et al.  Structure/function studies of HIV-1(1) reverse transcriptase: dimerization-defective mutant L289K. , 1993, Biochemistry.

[55]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Boyer,et al.  Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase , 1992, Journal of virology.

[57]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[58]  R. Goody,et al.  RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms , 1992, FEBS letters.

[59]  J. Maizel,et al.  HIV-1 reverse transcriptase: structure predictions for the polymerase domain. , 1990, AIDS research and human retroviruses.

[60]  M. A. McClure,et al.  Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[61]  D. Birx,et al.  Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. , 2004, AIDS reviews.

[62]  E. De Clercq,et al.  Antivirals and antiviral strategies. , 2004, Nature reviews. Microbiology.

[63]  Amalio Telenti,et al.  Update of the drug resistance mutations in HIV-1: 2004. , 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[64]  S. Yerly,et al.  Travel and the spread of HIV-1 genetic variants. , 2003, The Lancet. Infectious diseases.

[65]  R. Shafer,et al.  Drug resistance mutations in HIV-1. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[66]  Soriano,et al.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. , 2001, AIDS.

[67]  B. Larder,et al.  Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .

[68]  L. Loeb,et al.  FUNCTIONAL MUTANTS OBTAINED BY RANDOM MUTAGENESIS COUPLED WITH GENETIC SELECTION IN ESCHERICHIA COLI , 1996 .